Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Dec 16, 2010


Title: Lipophilic Conjugated iRNA Agents

Patent Number: 7,851,615

Filed: Aug. 3, 2007

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

"The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose," the patent's abstract states. "The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated … by using the non-ribose moiety as a point to which a ligand or other entity … [such as] a lipophilic moiety is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents."

Title: Development of Asthma Therapy with rAAV-Mediated AMCase shRNA

Patent Number: 7,851,616

Filed: Dec. 4, 2008

Lead Inventor: Chao-Lin Liu, MingChi University of Technology

"The invention provides small interfering RNA and their carriers that could treat asthma in mammalian [species] through inhibiting acidic mammalian chitinase gene expression," the patent's abstract states. "The invention further provides a composition comprising siRNA of the … invention and a carrier. The invention also provides a method for treating asthma of a subject."

Title: let-7 microRNA and Mimetics Thereof as Therapeutics for Cancer

Application Number: 20100310583

Filed: Jan. 31, 2008 PCT Filed: Jan. 31, 2008

Lead Inventor: Judy Lieberman, Harvard University

The invention, the patent application's abstract states, "relates to methods to treat or prevent cancers in a subject … [by] targeting cancer stem cells [with] miRNAs [that] have reduced expression or are lacking in cancer stem cells. In some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs.

"In alternative embodiments, the … invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs [that] have increased expression levels in the cancer stem cells," it adds. Other aspects of the invention relate to "methods to enrich for a cancer stem cell population … [and] methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells."

Title: Methods, Compositions, and Drug-Delivery Systems for Intraocular Delivery of siRNA Molecules

Application Number: 20100311808

Filed: Dec. 21, 2009

Lead Inventor: Robert Lyons, Allergan

The invention, the patent application's abstract states, comprises "biocompatible intraocular drug-delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug-delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others."

Title: Viral Vector System, a Composition Comprising the Viral Vector System, and Its Use

Application Number: 20100311809

Filed: Oct. 27, 2008 PCT Filed: Oct. 27, 2008

Lead Inventor: Henry Fechner, Charite-Universitatsmedizin Berlin

The invention "relates to a viral vector system comprising at least one viral vector and at least one [regulatable] expression cassette inserted in said viral vector applicable for the treatment of virally infected cells," the patent application's abstract states. "Preferably, the at least one [regulatable] expression cassette comprises at least one transactivator, at least one promoter, and at least one nucleotide sequence coding for a transgene, preferably a fusion protein. The … invention also relates to a composition comprising said viral vector and antiviral siRNAs for treatment of virally infected cells."

Title: RNA Interference-Mediated Inhibition of Intracellular Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100311812

Filed: July 16, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression and/or activity by RNA interference using small nucleic acid molecules."

Title: miR-101 Cancer Markers

Application Number: 20100311815

Filed: Feb. 23, 2010

Lead Inventor: Arul Chinnaiyan, University of Michigan

The invention, the patent application's abstract states, "relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. The … invention further provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.